PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells

Journal of Endocrinology

Volumn 208, Issue 1, 2011, Pages

  Hu, Yunshan ^a   Liu, Hong Bin ^a   Simpson, Richard W ^a,b   Dear, Anthony E ^a  

^a MONASH UNIVERSITY   (Australia)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; NUCLEAR RECEPTOR NUR77; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PPAR GAMMA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650974236     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-10-0393     Document Type: Article

References (31)

1. Baker KD, Shewchuk LM, Kozlova T, Makishima M, Hassell A, Wisely B, Caravella JA, Lambert MH, Reinking JL, Krause H et al. 2003 The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell 113 731-742. (doi:10.1016/S0092-8674(03)00420-3)
2. Bar-Tana J 2001 Peroxisome proliferator-activated receptor γ (PPAR) activation and its consequences in humans. Toxicology Letters 120 9-19. (doi:10.1016/S0378-4274(01)00302-2)
3. Costa M & Medcalf RL 1996 Differential binding of cAMP-responsive-element (CRE)-binding protein-1 and activating transcription factor-2 to a CRE-like element in the human tissue-type plasminogen activator (t-PA) gene promoter correlates with opposite regulation of t-PA by phorbol ester in HT-1080 and HeLa cells. European Journal of Biochemistry 237 532-538. (doi:10.1111/j.1432-1033.1996.00532.x)
4. Devaraj S, Xu DY & Jialal I 2003 C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 398-404. (doi:10.1161/01.CIR.0000052617.91920.FD)
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD et al. 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 1279-1289. (doi:10.1016/S0140-6736(05)67528-9)
6. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K & Lefebvre J 2000 Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells. Diabetologia 43 1165-1169. (doi:10.1007/s001250051508)
7. Eitzman DT, Westrick RJ, Xu Z, Tyson J & Ginsburg D 2000 Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96 4212-4215.
8. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I et al. 2003 Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNFα -induced PAI-1 expression. Blood 101 3042-3248. (doi:10.1182/blood-2002-07-2331)
9. He YW 2002 Orphan nuclear receptors in T lymphocyte development. Journal of Leukocyte Biology 72 440-446 (Review).
10. Hobb FD 2006 Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals. Atherosclerosis 7 29-32.
11. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ & RECORD Study Group 2007 Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine 357 28-38. (doi:10.1056/NEJMoa073394)
12. Iwasaki K, Matsumoto T, Aono H, Furukawa H & Samukawa M 2008 Prevalence of subclinical atherosclerosis in asymptomatic diabetic patients by 64-slice computed tomography. Coronary Artery Disease 19 195-201. (doi:10.1097/MCA.0b013e3282f3fbef)
13. Kumar S, Singh BK, Pandey AK, Kumar A, Sharma SK, Raj HG, Prasad AK, Van der Eycken E, Parmar VS & Ghosh B 2007 A chromone analog inhibits TNF-α induced expression of cell adhesion molecules on human endothelial cells via blocking NF-κB activation. Bioorganic and Medicinal Chemistry 15 2952-2962. (doi:10.1016/j.bmc.2007.02.004) (Pubitemid 46402972)
14. Liu HB, Hu YS, Medcalf RL, Simpson RW & Dear AE 2005 Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation. Biochemical and Biophysical Research Communications 334 30-37. (doi:10.1016/j.bbrc.2005.06.055)
15. Liu HB, Hu Y, Simpson RW & Dear AE 2008 Glucagon-like peptide-1 attenuates tumour necrosis factor-α-mediated induction of plasmogen activator inhibitor-1 expression. Journal of Endocrinology 196 57-65. (doi:10.1677/JOE-07-0387)
16. Mao LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH et al. 2004 Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 336-346. (doi:10.2337/diabetes.53.2.336)
17. Milbrandt J 1988 Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron 1 183-188. (doi:10.1016/0896-6273(88)90138- 9)
18. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y & Nawata H 1994 Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Medicine 11 685-691. (doi:10.1111/j.1464-5491.1994. tb00333.x)
19. Morigi M, Zoja C, Colleoni S, Angioletti S, Imberti B, Remuzzi A & Remuzzi G 1998 Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF-κB. Xenotransplantation 5 57-60. (doi:10.1111/j.1399-3089.1998.tb00009.x)
20. Nissen SE & Wolski K 2010 Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine (In Press).
21. Norata GD, Grigore L, Raselli S, Seccomandi PM, Hamsten A, Maggi FM, Eriksson P & Catapano AL 2006 Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. Journal of Molecular and Cellular Cardiology 40 484-494. (doi:10.1016/j.yjmcc.2006.01.022)
22. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK & O'Rahilly S 2001 Potentiation of glucose uptake in 3T3-L1 adipocytes by PPARγ agonists is maintained in cells expressing a PPARγ dominant-negative mutant: evidence for selectivity in the downstream responses to PPARγ activation. Molecular Endocrinology 15 1729-1738. (doi:10.1210/me.15.10.1729)
23. Osborn L, Kunkel S & Nabel GJ 1989 Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. PNAS 86 2336-2340. (doi:10.1073/pnas.86.7.2336)
24. Pei L, Castrillo A, Chen M, Hoffmann A & Tontonoz P 2005 Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. Journal of Biological Chemistry 280 29256-29262. (doi:10.1074/jbc.M502606200)
25. Pei L, Castrillo A & Tontonoz P 2006 Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Molecular Endocrinology 20 786-794. (doi:10.1210/me.2005-0331)
26. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P & Drouin J 1997 Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Molecular and Cellular Biology 17 5946-5951.
27. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E & Wahli W 2002 A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Molecular Endocrinology 16 2628-2644. (doi:10.1210/me.2002-0036)
28. Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, Xu H, Walker NP & Perlmann T 2003 Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423 555-560. (doi:10.1038/ nature01645)
29. Wilson TE, Fahrner TJ, Johnston M & Milbrandt J 1991 Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science 252 1296-1300. (doi:10.1126/science.1925541)
30. Willson TM, Lambert MH & Kliewer SA 2001 Peroxisome proliferator-activated receptor γ and metabolic disease. Annual Review of Biochemistry 70 341-367 (Review). (doi:10.1146/annurev.biochem.70.1.341)
31. Wöhrle J, Marx N, Koenig W, Hombach V, Kestler HA, Höher M & Nusser T 2008 Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clinical Research in Cardiology 97 726-733. (doi:10.1007/s00392-008-0663-8)